Based on the data presented in Figure 2C, normal tissue samples from the GTEx dataset were incorporated as controls, we evaluated the differential expression of CDCA5 between normal and tumor tissues in Lymphoid neoplasm diffuse large B-cell lymphoma (DLBC), Acute myeloid leukemia (LAML), Ovarian serous cystadenocarcinoma (OV), Pancreatic adenocarcinoma (PAAD), Sarcoma (SARC), Skin cutaneous melanoma (SKCM), Thymoma (THYM) and Uterine carcinosarcoma (UCS) with a significance level of P <0.05. Here, CDCA5 is linked to sarcoma.